Literature DB >> 9120822

Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung.

F Komada1, S Iwakawa, N Yamamoto, H Sakakibara, K Okumura.   

Abstract

Proteins of high molecular weight and low lipophilicity must be administered parenterally to achieve the desired therapeutic blood levels. We investigated the absorption of peptide and protein agents by rat lung following their intratracheal administration, expressing it as percent bioavailability. An aqueous solution and/or a dry powder of calcitonin, insulin, thyrotropin stimulating hormone (TSH), follicle stimulating hormone (FSH), and human chorionic gonadotropin (HCG) was delivered into the exposed trachea of anesthetized rats, and blood was sampled from the jugular vein at specified intervals. The bioavailabilities of TSH, FSH, and HCG delivered in a solution of neutral pH were 2.5, 2.3, and 0.2 %, respectively. Transpulmonary absorption of a solution of these agents, administered with a surfactant or under acidic conditions, was 2-30 times greater than the values obtained in controls. The bioavailabilities of calcitonin, insulin, TSH, FSH, and HCG, given intratracheally as a dry powder, were 11.5, 6.5, 1.6, 0.6, and 0.1%, respectively. Following intratracheal administration, we noted a negative association between molecular weight and bioavailability. The intratracheal route may thus be useful for delivering peptide and protein agents.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 9120822     DOI: 10.1002/jps.2600830621

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  15 in total

1.  Systemic delivery of cetrorelix to rats by a new aerosol delivery system.

Authors:  R Lizio; T Klenner; A W Sarlikiotis; P Romeis; D Marx; T Nolte; W Jahn; G Borchard; C M Lehr
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

2.  Inhaled insulin is better absorbed when administered as a dry powder compared to solution in the presence or absence of alkylglycosides.

Authors:  Alamdar Hussain; Quamrul H Majumder; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2006-12-07       Impact factor: 4.200

3.  A comparison of the pulmonary bioavailability of powder and liquid aerosol formulations of salmon calcitonin.

Authors:  Andrew Clark; Mei-Chang Kuo; Stephen Newman; Peter Hirst; Gary Pitcairn; Matt Pickford
Journal:  Pharm Res       Date:  2008-02-21       Impact factor: 4.200

4.  Inhalable lactose-based dry powder formulations of low molecular weight heparin.

Authors:  Shuhua Bai; Vivek Gupta; Fakhrul Ahsan
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

5.  Polyketal microparticles for therapeutic delivery to the lung.

Authors:  Vincent F Fiore; Megan C Lofton; Susanne Roser-Page; Stephen C Yang; Jesse Roman; Niren Murthy; Thomas H Barker
Journal:  Biomaterials       Date:  2009-10-20       Impact factor: 12.479

6.  Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats.

Authors:  S Kobayashi; S Kondo; K Juni
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

7.  The pulmonary absorption of aerosolized and intratracheally instilled rhG-CSF and monoPEGylated rhG-CSF.

Authors:  R W Niven; K L Whitcomb; L Shaner; A Y Ip; O B Kinstler
Journal:  Pharm Res       Date:  1995-09       Impact factor: 4.200

8.  Immediate and short-term cellular and biochemical responses to pulmonary single-dose studies of insulin and H-MAP.

Authors:  L Garcia-Contreras; D Sarubbi; E Flanders; D O'Toole; J Smart; C Newcomer; A J Hicke
Journal:  Pharm Res       Date:  2001-12       Impact factor: 4.200

9.  Evaluation of novel particles as pulmonary delivery systems for insulin in rats.

Authors:  Lucila Garcia-Contreras; Tülin Morçöl; Steve J D Bell; Anthony J Hickey
Journal:  AAPS PharmSci       Date:  2003

10.  Complexation of a poly-L-arginine with low molecular weight heparin enhances pulmonary absorption of the drug.

Authors:  Amit Rawat; Tianzhi Yang; Alamdar Hussain; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2007-10-23       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.